Dr. Rajesh Jain
#990Chairman and Managing Director
60
Age
20y
Exp
41y
Tenure
8/10
Risk
🎓 B.Sc. · University of Delhi
📜 PGDBM + Ph.D (Business Admin) · Shivaji Inst of Mgmt, Ghaziabad + BIMTECH/Ambedkar Univ
🏛️ None
CompensationTBP
Personality
8
Open
7
Cons
6
Extr
6
Agre
4
Neur
Panacea Biotec
Healthcare · Small Cap
Distressed / Turnaround · Founder-Centric
About
Dr. Rajesh Jain is the Chairman and Managing Director of Panacea Biotec, a Small Cap company in the Healthcare sector with a market cap of ₹2K Cr. A Visionary leader with 20 years of experience, he is known for intuition-driven decision-making and partnership seeker strategy. Demonstrates high risk-taking through long-cycle investments in proprietary vaccine R&D and global clinical trials.
FAQ
What is Dr. Rajesh Jain's leadership style?
Dr. Rajesh Jain is classified as a Visionary leader. He is intuition-driven in decision-making, with a innovation motivation and seasonal-burst pace of execution.
What is Dr. Rajesh Jain's educational background?
Dr. Rajesh Jain holds a B.Sc. from University of Delhi and a PGDBM + Ph.D (Business Admin) from Shivaji Inst of Mgmt, Ghaziabad + BIMTECH/Ambedkar Univ.
Who is the CEO of Panacea Biotec?
Dr. Rajesh Jain is the Chairman and Managing Director of Panacea Biotec. He has been with the company for 41 years and in the current role for 7 years.
Leadership DNA
ArchetypeVisionary
MotivationInnovation
CrisisAggressive Pivoter
DecisionIntuition-Driven
GrowthPartnership Seeker
PeopleInstitution Builder
InnovationDisruptor
PaceSeasonal-Burst
PurposeMission-First
CustomerB2G-Institutional
EmployerLearning Ground
BrandTechnical-Expert
FocusProduct Innovation
OrientationDeep Specialist
Leadership Evidence
“Demonstrates high risk-taking through long-cycle investments in proprietary vaccine R&D and global clinical trials.”
⚡ Crisis●●●●○
Demonstrated agility by pivoting the company's focus toward COVID-19 vaccine development and international partnerships during the pandemic.
🎯 Motivation●●●●●
Deeply rooted in R&D-led growth, focusing on complex vaccines and novel drug delivery systems throughout his tenure.
👥 People●●●●○
Focuses on building long-term scientific capabilities and infrastructure rather than short-term transactional management.
📈 Growth●●●●●
Extensive history of leveraging global collaborations and joint ventures to scale vaccine and pharmaceutical manufacturing.
💡 Innovation●●●●○
The company historically pioneered the development of India's first fully indigenously developed acellular pertussis-based combination vaccine.
🏃 Pace●●●○○
As a biotech firm heavily reliant on regulatory approvals and large-scale government immunization tenders, its operational rhythm is dictated by project cycles.
🌱 Purpose●●●●○
The company's core identity is built around affordable healthcare access through complex vaccine and biotechnology R&D.
🏷️ Brand●●●●○
The company is recognized by industry peers for its deep technical capabilities in complex drug delivery systems and vaccine technology.
🤝 Customer●●●●○
A significant portion of its revenue is derived from supplying vaccines to government immunization programs and international health institutions.
💼 Employer●●●○○
It is viewed as a specialized technical environment where scientists and researchers gain niche experience in complex vaccine manufacturing.
📋 Mandate
The firm requires a leadership shift to stabilize finances and streamline its R&D pipeline after prolonged periods of financial pressure.
🏢 Culture●●●●○
Dr. Rajesh Jain remains the central authority driving the R&D and strategic turnaround efforts.
Financials
Revenue FY25₹493 Cr
PAT FY25₹-83700000
Rev CAGR 5Y-9.3%
OPM-11.3%
NPM-1.7%
ROE-1%
ROCE-6%
P/E—
Fwd P/E—
P/B2.4
D/E2.8
Promoter72.7%
Institutional0.1%
Mkt Cap₹2K Cr
Compensation
To Be Published
Data being verified from audited reports
